Dave Turkaly: Great, thanks. Laura, given the numbers that you saw in the fourth quarter, the 30% plus procedure volume growth, I’m just trying to reconcile with what we’ve heard from some of the, let’s say, some of the other competitors in the ortho spine world, but in terms of where you think we are coming out or the rebound from COVID, I mean it seems like your U.S. might be all the way back and maybe you still have some lingering OUS things to tackle, but I heard you mentioned freight, but I didn’t hear you say anything about staffing shortages. I know you said depreciation as well, but I’d just like to get your thoughts on domestically, do you feel like we’re back?
Laura Francis: You know, it’s an interesting question. We’re looking at this as a normalized operating environment. And if anything, I was frustrated at the fact that it took four quarters in order to really see it. But we’re pretty excited about where we’re at. I do think that if I think about our procedures, Dave, our procedure is a relatively straightforward procedure in the operating room. For the most part, it’s done outpatient or in a surgery center. And I think that even with a squeeze on labor in some cases, the sites of service and the surgeons are able to squeeze in these procedures. I do think that some of these improvements that we’ve seen in reimbursement will have an impact on the procedure being prioritized as well. And so I think all of those things are working in our favor.
Dave Turkaly: Got it. And then maybe a quick follow-up just on the M&A landscape. We’ve seen some things start to happen again, which is nice, but it’s been a little bit of a delay there. I guess I’d sort of like to hear your thoughts on where you’re getting some of the new reps and where you plan to bring that force to this year? And if you think any of the transactions might help you gain some competitive folks?
Laura Francis: It’s definitely interesting to watch what’s going on at this point. It does seem like the M&A environment has come back to life, because 2022 was pretty quiet at least in our particular space. So we’re actually happy to see it. We — there’s a couple of things from a rep perspective. We’ve done a very good job of retaining our key reps within SI-BONE. And then we’ve also done a good job of growing our reps, too. So hiring these more junior clinical support specialists in 50% of cases when we do split a territory, we actually promote a clinical support specialist into a territory manager. So we try and promote from within wherever we can does it provide additional opportunity for us to hire new. Our focus is more on getting leverage of the sales force in 2023.
So growing that $1.2 million of productivity up to the $1.5 million to $2 million range depending upon whether there’s a junior rep in the territory or not. And so I would say that our thoughts are more on productivity increases and growing our own sales force versus trying to pull from other places given some of these changes in the M&A landscape.
Dave Turkaly: Thank you.
Laura Francis: Thanks, Dave.
Operator: Thank you. Our next question comes from the line of Drew Ranieri with Morgan Stanley. Your line is open.
Drew Ranieri: Thanks for taking the questions, Laura Anshul. Maybe just on the overall environment. I mean, a few companies have talked about softness in the fourth quarter. This may go back to a question that was already asked. But as you are seeing about rolling out Granite through €˜23, can you just maybe talk about any factors that you are seeing in terms of growth rate and adoption? Are you seeing these incremental headwinds affecting the Granite launch? And then just from a set perspective, do you think — or at this point, do you have adequate supply to meet all demand in the marketplace right now? And I have a follow-up.
